

RECEIVED
CENTRAL FAX CENTER

NOV 29 2006

PATENT
Application No. 10/826,929
Attorney Docket No. 57657/04-265
Page 3 of 10*Amendments to the Claims*

The following is a complete listing of all claims in the application, with an indication of the status of each; this listing of claims will replace all prior versions, and listing, of claims in the application.

Listing of claims:

1. (Currently amended) A vaccine for equine influenza virus, comprising:

an effective immunizing amount of an isolated DNA, the isolated comprising sequences that encode at least a fragment of an HA1 protein from which HA2 is absent, the sequences being from a strain of equine-2 influenza virus; and
a pharmacologically acceptable carrier or diluent.

2. (Previously presented) The vaccine according to claim 1, wherein the strain of equine-2 influenza virus is selected from the group consisting of A/Eq/Kentucky/98, A/Eq/Miami/63, A/Eq/Kentucky/81, A/Eq/Fontainebleau/79, A/Eq/Kentucky/94, A/Eq/Newmarket/2/93, A/Eq/New York/99, and A/Eq/Oklahoma/2000.

3. (Previously presented) The vaccine according to claim 1, wherein the strain is A/Eq/Kentucky/98.

PATENT
Application No. 10/826,929
Attorney Docket No. 57657/04-265
Page 4 of 10

4. (Previously presented) The vaccine according to claim 1, wherein the sequences that encode an HA1 protein from which HA2 is absent comprise the nucleotide sequence of SEQ ID NO: 1.
5. (Original) The vaccine according to claim 1, further comprising one or more of the group consisting of additional antigenic components, encoding sequences for additional antigenic components, and other vaccines.
6. (Previously presented) The vaccine according to claim 1, further comprising a vector containing the sequences that encode an HA1 protein from which HA2 is absent.
7. (Original) The vaccine according to claim 6, wherein the vector is a eukaryotic expression vector.
8. (Original) The vaccine according to claim 7, wherein the vector is selected from the group consisting of pcDNA3.1/V5-His-TOPO and pVAX1.
9. (Original) The vaccine according to claim 1, further comprising an adjuvant.

PATENT

Application No. 10/826,929

Attorney Docket No. 57657/04-265

Page 5 of 10

10. (Original) The vaccine according to claim 9, wherein the adjuvant is selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels, surface active substances, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, and dinitrophenol.
11. (Canceled).
12. (Previously presented) The vaccine according to claim 1, further comprising a liposome into which the sequences that encode an HA1 protein from which HA2 is absent is encapsulated.
13. (Original) A method of inducing an immune response against equine influenza virus, comprising administering to an equid an effective immunizing amount of the vaccine of claim 1.
14. (Previously presented) The method according to claim 13, further comprising the steps of inserting the sequences that encode an HA1 protein from which HA2 is absent into a vector and delivering the vaccine intranasally into the respiratory tract.
15. (Original) The method according to claim 14, wherein the vector is a eukaryotic vector.

PATENT
Application No. 10/826,929
Attorney Docket No. 57657/04-265
Page 6 of 10

16. (Original) The method according to claim 15, wherein the vector is selected from the group consisting of pcDNA3.1/V5-His-TOPO and pVAX1.
17. (Previously presented) The method according to claim 15, wherein the vector is a liposome.
18. (Original) The method according to claim 13, wherein the vaccine is administered at a dosage of at least 0.01 μg DNA per gram of body weight.
19. (Original) The method according to claim 13, wherein the vaccine is administered at a dosage falling within the range of 0.001 μg DNA per kilogram of body weight to 0.01 μg DNA per gram of body weight.